Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Tesch

Showing results (101-110 of 171) with videos related to

Pageof 18
Sort By:
Breast Cancer Research : BCR|May 12, 2019
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixtoElena Laakmann, Isabell Witzel, Peter A Fasching, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
Cancers|April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer PatientsHanna Huebner, Lothar Häberle, Volkmar Müller, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trialAndreas Schneeweiss, Volker Möbus, Hans Tesch, et al.
Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
BMC Medicine|October 8, 2024
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER<sup>+</sup> breast cancerPhilipp Zimmer, Tobias Esser, Diana Lueftner, et al.
Geburtshilfe Und Frauenheilkunde|March 14, 2022
Correction: Update Breast Cancer 2021 Part 5 - Advanced Breast CancerDiana Lüftner, Florian Schütz, Elmar Stickeler, et al.
Pageof 18

Showing results (101-110 of 171) with videos related to

Sort By:
Pageof 18
Breast Cancer Research : BCR|May 12, 2019
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixtoElena Laakmann, Isabell Witzel, Peter A Fasching, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
Cancers|April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer PatientsHanna Huebner, Lothar Häberle, Volkmar Müller, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trialAndreas Schneeweiss, Volker Möbus, Hans Tesch, et al.
Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
BMC Medicine|October 8, 2024
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER<sup>+</sup> breast cancerPhilipp Zimmer, Tobias Esser, Diana Lueftner, et al.
Geburtshilfe Und Frauenheilkunde|March 14, 2022
Correction: Update Breast Cancer 2021 Part 5 - Advanced Breast CancerDiana Lüftner, Florian Schütz, Elmar Stickeler, et al.
Pageof 18